156 related articles for article (PubMed ID: 26455717)
1. High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.
Cassaday RD; Stevenson PA; Gooley TA; Chauncey TR; Pagel JM; Rajendran J; Till BG; Philip M; Orozco JJ; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Smith SD; Libby EN; Maloney DG; Press OW; Gopal AK
Br J Haematol; 2015 Dec; 171(5):788-97. PubMed ID: 26455717
[TBL] [Abstract][Full Text] [Related]
2. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Kruger PC; Cooney JP; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
[TBL] [Abstract][Full Text] [Related]
3. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.
Behr TM; Griesinger F; Riggert J; Gratz S; Béhé M; Kaufmann CC; Wörmann B; Brittinger G; Becker W
Cancer; 2002 Feb; 94(4 Suppl):1363-72. PubMed ID: 11877767
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma.
Shimoni A; Zwas ST
Semin Nucl Med; 2016 Mar; 46(2):119-25. PubMed ID: 26897716
[TBL] [Abstract][Full Text] [Related]
5. Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.
Wagner JY; Schwarz K; Schreiber S; Schmidt B; Wester HJ; Schwaiger M; Peschel C; von Schilling C; Scheidhauer K; Keller U
Oncotarget; 2013 Jun; 4(6):899-910. PubMed ID: 23765188
[TBL] [Abstract][Full Text] [Related]
6. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
7. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.
Graf SA; Stevenson PA; Holmberg LA; Till BG; Press OW; Chauncey TR; Smith SD; Philip M; Orozco JJ; Shustov AR; Green DJ; Libby EN; Bensinger WI; Pagel JM; Maloney DG; Zhou Y; Cassaday RD; Gopal AK
Ann Oncol; 2015 Nov; 26(11):2323-8. PubMed ID: 26347113
[TBL] [Abstract][Full Text] [Related]
8. Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma.
Berger MD; Branger G; Klaeser B; Taleghani BM; Novak U; Banz Y; Mueller BU; Pabst T
Hematol Oncol; 2016 Sep; 34(3):133-9. PubMed ID: 25689832
[TBL] [Abstract][Full Text] [Related]
9. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).
García-Noblejas A; Cannata-Ortiz J; Conde E; González Barca E; Gutiérrez N; Rojas R; Vidal MJ; Ramírez MJ; Jiménez-Ubieto A; García-Ruiz JC; Sancho JM; López A; Ríos Rull P; Novelli S; Albo C; Debén G; López-Guillermo A; Nicolás C; González de Villambrosia S; Mercadal S; Martín García-Sancho A; Arranz R
Ann Hematol; 2017 Aug; 96(8):1323-1330. PubMed ID: 28536895
[TBL] [Abstract][Full Text] [Related]
10. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
[TBL] [Abstract][Full Text] [Related]
11. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M
Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438
[TBL] [Abstract][Full Text] [Related]
12. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
[TBL] [Abstract][Full Text] [Related]
13. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
[TBL] [Abstract][Full Text] [Related]
14. Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma.
Derenzini E; Stefoni V; Maglie R; Casadei B; Pellegrini C; Broccoli A; Stefani G; Fanti S; Motta MR; Narducci R; Argnani L; Zinzani PL
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1695-701. PubMed ID: 24055654
[TBL] [Abstract][Full Text] [Related]
15. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.
Nademanee A; Forman SJ
Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.
Gisselbrecht C; Vose J; Nademanee A; Gianni AM; Nagler A
Oncologist; 2009; 14 Suppl 2():41-51. PubMed ID: 19819923
[TBL] [Abstract][Full Text] [Related]
17. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.
Gopal AK; Gooley TA; Maloney DG; Petersdorf SH; Eary JF; Rajendran JG; Bush SA; Durack LD; Golden J; Martin PJ; Matthews DC; Appelbaum FR; Bernstein ID; Press OW
Blood; 2003 Oct; 102(7):2351-7. PubMed ID: 12750161
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
19. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW
J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.
Gopal AK; Rajendran JG; Petersdorf SH; Maloney DG; Eary JF; Wood BL; Gooley TA; Bush SA; Durack LD; Martin PJ; Matthews DC; Appelbaum FR; Bernstein ID; Press OW
Blood; 2002 May; 99(9):3158-62. PubMed ID: 11964278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
